Decheng Capital Management Iii (Cayman), LLC Adicet Bio, Inc. Transaction History
Decheng Capital Management Iii (Cayman), LLC
- $181 Million
- Q3 2023
A detailed history of Decheng Capital Management Iii (Cayman), LLC transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Decheng Capital Management Iii (Cayman), LLC holds 200,201 shares of ACET stock, worth $184,184. This represents 0.15% of its overall portfolio holdings.
Number of Shares
200,201
Previous 505,668
60.41%
Holding current value
$184,184
Previous $1.23 Million
77.69%
% of portfolio
0.15%
Previous 0.65%
Shares
3 transactions
Others Institutions Holding ACET
# of Institutions
72Shares Held
59.2MCall Options Held
4.2KPut Options Held
6.7K-
Orbimed Advisors LLC San Diego, CA11.4MShares$10.5 Million0.39% of portfolio
-
Tang Capital Management LLC San Diego, CA8.22MShares$7.56 Million1.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.54MShares$6.94 Million0.15% of portfolio
-
Goldman Sachs Group Inc New York, NY3.76MShares$3.46 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.21MShares$2.95 Million0.0% of portfolio
About Adicet Bio, Inc.
- Ticker ACET
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,030,800
- Market Cap $36.8M
- Description
- Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...